Abstract:Background Epstein Barr virus (EBV) is a highly prevalent herpesvirus worldwide and its infection is associated with malignancies such as nasopharyngeal cancer (NPC), gastric cancer, lymphoepithelioma cancer and lymphoproliferative disorders. Virus-specific T (VST) cell therapies using T cells reactive against EBV have shown limited efficacy in clinical trials with several practical limitations such as the long preparation period and the variations of pre-existing EBV-reactive T cells in different donors. To overcome these technical constraints of the VST approach, we have established the genetically engineered T cells targeting EBV antigens with lentiviral transduction. A proof-of-concept clinical validation was further conducted against EBV+ malignancies (trial No. ChiCTR2100044497). Methods T cells were activated by CD3/CD28 stimulation, lentivirally transduced with codon-optimized CAR (targeting EBV envelope protein) or TCR (targeting EBV latent membrane protein) and further expanded ex vivo. Transgene expression and the T cell phenotype were assessed by flow cytometry. In vitro anti-tumor efficacy was analyzed by IFN-γ ELISA and killing assays such as RTCA Xcelligence. In vivo, the antitumor efficacy of EBV-specific T cells was evaluated in immunocompromised mice bearing human tumor xenografts. Anti-tumor responses in lymphoma and NPC were evaluated by Lugano 2014 and RECIST 1.1 respectively. Results T cells lentivirally transduced with EBV antigen-specific CAR or TCR demonstrated satisfactory surface expression of the introduced receptor and showed increased cytokine production when stimulated to target expressing tumor cells in vitro (figure 1). We have identified the TCRs against EBV latent membrane protein with high functional avidity as determined by peptide dose-response functional assays. In vitro cytotoxicity assays demonstrated strong killing of antigen positive tumor cell lines of the engineered EBV-specific CAR-T or TCR-T cells, while sparing the antigen-negative cells, indicating the specific T cell response. The single intravenous infusion of engineered EBV-specific T cells also led to dose-dependent anti-tumor responses in immunocompromised mouse xenograft models (figure 1). In the clinical trial, two patients with lymphoproliferative disease and one patient with advanced NPC treated with engineered EBV-targeting T cells experienced sustained objective responses. Moreover, in the NPC patient, the EBV DNA copy number decreased from 3.32*103 copies/ml at baseline to normal (<5.00*102 copies/ml) 2 months post infusion. The infused cells also demonstrated satisfactory safety profile with no neurotoxicity and ≥ Grade 2 cytokine release syndrome observed. Conclusions Our data demonstrate the feasibility of using genetically engineered T cells targeting EBV antigens such as envelope protein or latent membrane protein to treat EBV-associated malignancies. Trial Registration Chinese Clinical Trial Registry: ChiCTR2100044497 Ethics Approval All animal studies were conducted at Guangzhou Regenerative Medicine and Health, Guangdong Laboratory as approved by IACUC (2020125). The clinical study was approved by the first affiliated hospital of Zhengzhou University's Ethics Board (L2021-Y027–005).

Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus–positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) in Patients with Refractory/metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label Phase II Clinical Study

Recombinant Humanised Anti-Pd-1 Monoclonal Antibody (js001) Treatment for Patients with Refractory or Metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label, Phase 1b/2, Clinical Study

Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial

TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

328 Preclinical Analyses and Proof of Concept Clinical Study of Epstein Barr Virus (EBV) Specific Genetically Modified T Cells Against EBV Associated Malignancies

Adjuvant Apatinib in Nasopharyngeal Carcinoma Patients with Residual Epstein-Barr Virus DNA after Curative Radiotherapy: A Phase IIa/IIb Trial.

Activation of Epstein–Barr Virus' Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma

Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy

Investigational drugs for nasopharyngeal carcinoma

Four-year Overall Survival Follow-Up and Dynamic EBV Titer Analysis of Toripalimab Versus Placebo in Combination with Gemcitabine and Cisplatin As First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (r/m NPC).

A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)

EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ill Study Of Anlotinib Or Placebo In Combination With Gemcitabine And Cisplatin (Gp) As First -Line Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma (R/M Npc).

Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.

Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: a Multicenter, Single-Arm, Phase 2 Study

Abstract 5786: Epstein-Barr virus nuclear antigen 1 (EBNA1)-targeting probes stimulate interferon-β production by nasopharyngeal carcinoma (NPC) cells to enhance the natural killer cell-mediated cytotoxicity against NPC

Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma

Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epstein–Barr Virus DNA after Radiotherapy

Reduced-dose Radiotherapy for Pretreatment EBV DNA Selected Low-Risk Stage III Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial.